• Quantum BioPharma shareholders authorized a consolidation of up to 10-for-1 at the November 10, 2026, annual general and special meeting.
• Disinterested shareholders approved continuing board authority to issue additional Class A Multiple Voting Shares to Permitted Holders.
• A name change received shareholder approval, with the board authorized to select the new name at its discretion.
• Shareholders adopted the omnibus equity incentive plan and elected all five director nominees.
• MNP LLP was reappointed auditor, with the audit committee authorized to set its remuneration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110707PRIMZONEFULLFEED9875355) on November 11, 2026, and is solely responsible for the information contained therein.